The PROfound study, which evaluated the efficacy of comprehensive gene profiling (CGP) in detecting BRCA1/2 somatic mutations, highlighted technical challenges to successfully implementing CGP in diagnostic routine practice for prostate cancer patients. The gene discussed is BRCA1; the disease is prostate cancer.